In our previous work, we built a full-length IgM model that demonstrated the potential of IgM antibodies in targeting cancer antigens, specifically on the ability of Pertuzumab IgM to bind multiple human epidermal growth factor receptor 2 (HER2) simultaneously, thus enhancing its inhibitory effect compared to IgG (24). This evidence concerns the gene CD40LG and cancer.